MFS
LCTX icon

Mirabella Financial Services’s Lineage Cell Therapeutics LCTX Stock Holding History

Mirabella Financial Services’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-74,065
Closed -$86.7K – 510
2022
Q4 		$86.7K Buy
+74,065
New +$93.3K 0.01% 350
2022
Q2 		– Sell
-18,800
Closed -$29K – 606
2022
Q1 		$29K Buy
+18,800
New +$29.2K ﹤0.01% 510
2021
Q1 		– Sell
-61,655
Closed -$109K – 359
2020
Q4 		$109K Buy
+61,655
New +$86.2K 0.01% 279

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mirabella Financial Services's LCTX Position: Q1 2023 in Review

Mirabella Financial Services sold out of Lineage Cell Therapeutics (LCTX) in Q1 2023, closing a stake of 74,065 shares — an estimated $86.7K sold.

Mirabella Financial Services first reported a position in LCTX in Q4 2020 and held it in 3 quarters. The position peaked at $109K in Q4 2020. 115 funds tracked by Wall St. Rank hold LCTX as of Q1 2023.

  • Mirabella Financial Services reported no remaining Lineage Cell Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Mirabella Financial Services sold 74,065 Lineage Cell Therapeutics shares in Q1 2023, an estimated $86.7K.
  • Mirabella Financial Services first reported a position in Lineage Cell Therapeutics in Q4 2020 and held it in 3 quarters.
  • Mirabella Financial Services's Lineage Cell Therapeutics position peaked at $109K in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2023.

Based on Mirabella Financial Services's 13F filing for Q1 2023, filed 12 May 2023.